Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Pre-Market Trading 11-05 07:41:05 EST

28.43

+0.50

+1.79%

High29.00	Low27.36	Vol136.94K
Open27.97	D1 Closing27.93	Amplitude5.87%
Mkt Cap781.73M	Tradable Cap355.73M	Total Shares27.50M
T/O3.89M	T/O Rate1.09%	Tradable Shares12.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":28.43,"timestamp":1730754000000,"preClose":27.93,"halted":0,"volume":136937,"delay":0,"floatShares":12512401,"shares":27496665,"eps":-4.263813,"marketStatus":"Pre-Market Trading","change":0.5,"latestTime":"11-05 07:41:05 EST","open":27.97,"high":29,"low":27.36,"amount":3887772.478709,"amplitude":0.058718,"askPrice":34.51,"askSize":100,"bidPrice":29.05,"bidSize":11692,"shortable":3,"etf":0,"ttmEps":-4.263813,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1730817000000},"marketStatusCode":1,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":28.43,"postHourTrading":{"tag":"盘后","latestPrice":28.43,"preClose":28.43,"latestTime":"16:58 EST","volume":2669,"amount":75885.27,"timestamp":1730757525501},"volumeRatio":0.9857681719789013},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"2481080685","title":"Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481080685","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481080685?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:30","pubTimestamp":1730809800,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, Nov.  05, 2024  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced pl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2974829/0/en/Plus-Therapeutics-to-Announce-Third-Quarter-Financial-Results-and-Host-Conference-Call-on-November-14-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","HST","BK4585","BK4139","BK4588","BK4181","BK4218"],"gpt_icon":0},{"id":"2481508626","title":"Entrada Therapeutics Says Cash Runway Expected Into 2027 With $449M In Cash, Cash Equivalents And Marketable Securities As Of September 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481508626","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481508626?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:26","pubTimestamp":1730809618,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics Says Cash Runway Expected Into 2027 With $449M In Cash, Cash Equivalents And Marketable Securities As Of September 30, 2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/11/41741782/entrada-therapeutics-says-cash-runway-expected-into-2027-with-449m-in-cash-cash-equivalents-and-m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","LENZ","BK4139"],"gpt_icon":0},{"id":"2481508623","title":"Entrada Therapeutics Q3 2024 GAAP EPS $(0.35) Beats $(0.78) Estimate, Sales $19.57M Beat $12.32M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481508623","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481508623?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:26","pubTimestamp":1730809570,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.78) by 55.13 percent.  The company reported quarterly sales of $19.57 million which beat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41741761/entrada-therapeutics-q3-2024-gaap-eps-0-35-beats-0-78-estimate-sales-19-57m-beat-12-32m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","LENZ"],"gpt_icon":0},{"id":"2481665508","title":"Neumora Therapeutics Cut to Neutral From Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2481665508","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481665508?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:25","pubTimestamp":1730809500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NMRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2024 07:25 ET (12:25 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","LENZ"],"gpt_icon":0},{"id":"2481357013","title":"PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2481357013","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481357013?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:05","pubTimestamp":1730808300,"startTime":"0","endTime":"0","summary":"BOSTON, November 05, 2024----PureTech Health plc  , a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics,  a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen  prior to its acquisition by AbbVie  for $10.1 billion in 2024.The full text of the announcement from Seaport is as follows:. Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations. Prior to that, Ms. White held roles of increasing responsibility at Novartis , most recently serving as Global Head of Financial Planning and Analysis for the Novartis Institutes for BioMedical Research , where she drove financial strategy and business plan","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_gffI1LxnXgj4iYsUFnmbQ--~B/aD0yMzYyO3c9NzM2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/ed3426fb12673755fb2daccf3a8f4e34","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_gffI1LxnXgj4iYsUFnmbQ--~B/aD0yMzYyO3c9NzM2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/ed3426fb12673755fb2daccf3a8f4e34"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/puretech-founded-entity-seaport-therapeutics-120500863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","MNQmain","PRTC","LENZ","IE00BJJMRZ35.SGD","LU0211328371.USD","LU0203347892.USD","LU0158827948.USD","LU0689472784.USD","LU0820561818.USD","SQQQ","WRD","BK4080","QID","LU0912757837.SGD","LU0965508806.USD","LU0882574055.USD","BK4534","LU0198837287.USD","LU0122379950.USD","IE0004445239.USD","NVS","QLD","LU0965509283.SGD",".IXIC","IE00BVYPNW00.USD","IMGN","LU0114720955.EUR","LU0310800379.SGD","NQmain","BK4532","IE00B3PB1722.GBP","IE00BGHQF631.EUR","CCCC","LU0965509101.SGD","IE00BSNM7G36.USD","IE00B42XCP33.USD","LU0456855351.SGD","LU0310799852.SGD","TQQQ","LU1003077747.HKD","LU0211331839.USD","LU0553294199.USD","LU0738911758.USD","LU0234570918.USD","ABBV","QQQ","PSQ","ADC","BK4550"],"gpt_icon":0},{"id":"2481772035","title":"Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2481772035","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481772035?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:00","pubTimestamp":1730808000,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 05, 2024  -- Applied Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California.Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor  for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rd.zdem6H.5iAKsFPsV9ow--~B/aD00NDc7dz0xNjU0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a642cfd9ca59150b84905e0421c4fb34","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rd.zdem6H.5iAKsFPsV9ow--~B/aD00NDc7dz0xNjU0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a642cfd9ca59150b84905e0421c4fb34"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/applied-therapeutics-present-2024-ubs-120000316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4110","HCSG","APLT","ARI","BK4139","LENZ","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","BK4137"],"gpt_icon":0},{"id":"2481705855","title":"TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2481705855","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481705855?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:00","pubTimestamp":1730808000,"startTime":"0","endTime":"0","summary":"BOSTON, Nov.  05, 2024  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2974769/0/en/TransCode-Therapeutics-Announces-Nasdaq-Extension-to-Regain-Compliance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4566","IE00BZ18W456.USD","IE00BMG7P694.USD","LU2210150020.SGD","LU2210149790.SGD","IE00B29SXK94.USD","IE00BMG7P926.USD","IE00BD4GTW91.USD","IE00B64PRP62.GBP","BK4588","BK4208","D","IE00B3T34201.USD","IE00BD4GTT62.SGD","IE00B3QW5Z07.USD","RNAZ","BK4585","MNQmain","PSQ","LENZ","NQmain","QID","IE00BKPKM429.USD","IE00BMG7P819.SGD","IE00BZ18W340.USD","IE00B29SXL02.USD","QLD","LU2095319765.USD","TQQQ","IE00BGHQF748.EUR","IE00BMQBXF63.USD","NDAQ","IE00BD4GTV84.USD","BK4139","SQQQ","IE00BMG7P702.HKD",".IXIC","IE00BMG7P587.USD"],"gpt_icon":1},{"id":"2481570924","title":"ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2481570924","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481570924?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:00","pubTimestamp":1730808000,"startTime":"0","endTime":"0","summary":"During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta cells.Preservin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2974772/0/en/ZyVersa-Therapeutics-Highlights-Published-Data-Demonstrating-the-Potential-of-Inflammasome-Inhibition-to-Protect-Pancreatic-Islet-Beta-Cells-and-Attenuate-Progression-from-Obesity-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2481570586","title":"Entrada Therapeutics Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481570586","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481570586?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:00","pubTimestamp":1730808000,"startTime":"0","endTime":"0","summary":"– Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – – On track to submit ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2974780/0/en/Entrada-Therapeutics-Reports-Third-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BK4532","IE0002270589.USD","LU0289739699.SGD","LU2362540622.SGD","LU0256863811.USD","VERX","LU2324357040.USD","IE00B4R5TH58.HKD","LU1093756168.USD","IE00B19Z3B42.SGD","BK4588","IE00B19Z9P08.USD","LENZ","TRDA","LU2462157665.USD","LU0417517546.SGD","LU0061475181.USD","LU0109394709.USD","LU1069344957.HKD","LU0823416689.USD","IE00B19Z9Z06.USD","IE0009355771.USD","IE00BZ9MQY76.HKD","BK4585","LU2417539215.USD","IE00BJJMRZ35.SGD","LU2456880835.USD","BK4023","LU0234570918.USD","BK4139","VRTX","LU0889565916.HKD","BK4567","IE00BJT1NW94.SGD","LU2236285917.USD","LU0058720904.USD","LU1093756325.SGD","LU0079474960.USD","BK4533","LU0320765992.SGD","IE0002141913.USD","IE00B894F039.SGD","LU1035775433.USD","LU2237438978.USD","LU2362541273.HKD","LU2362541513.USD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU1585245621.USD"],"gpt_icon":0},{"id":"2481570580","title":"SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2481570580","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481570580?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:00","pubTimestamp":1730808000,"startTime":"0","endTime":"0","summary":"STAMFORD, Conn., Nov.  05, 2024  (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today annou","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2974794/0/en/SpringWorks-Therapeutics-to-Participate-in-Guggenheim-s-Inaugural-Healthcare-Innovation-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","HCSG","BK4137"],"gpt_icon":0},{"id":"2481503365","title":"Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481503365","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481503365?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:00","pubTimestamp":1730808000,"startTime":"0","endTime":"0","summary":"– Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing in studies of zorevunersen by year-end –。– As of September 30, 2024, Company had $269.2 million in cash, cash equivalents, and marketable securities –。\"We are headed into a busy year-end as we prepare to share new data which is representative of our proposed Phase 3 dosing regimen and complete our regulatory discussions toward alignment on that study design,\" said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. \"Key to our regulatory discussions are the assessments of behavior and cognition in patients with Dravet syndrome. In our studies of zorevunersen, we have demonstrated substantial and sustained effects across multiple measures of disease, starting within the first year of treatment. These data give us confidence in our Phase 3 planning and the potential for zorevunersen to go beyond seizure management","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LY.RmCyloYSVIGM0btlSSQ--~B/aD0yMjM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cea2472cd578945bbcf66dde3c0d39bf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LY.RmCyloYSVIGM0btlSSQ--~B/aD0yMjM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cea2472cd578945bbcf66dde3c0d39bf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/stoke-therapeutics-reports-third-quarter-120000325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4200","IE0002270589.USD","AES","BK4561","BK4105","BK4139","BK4519","LENZ","LU0061475181.USD","LU1093756325.SGD","LU1093756168.USD","IE00B19Z3B42.SGD","ASO","BK4585","STOK","BK4588","IE00B7SZLL34.SGD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2481574479","title":"Beam Therapeutics reports Q3 EPS ($1.17), consensus ($1.13)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481574479","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481574479?lang=en_us&edition=fundamental","pubTime":"2024-11-05 19:35","pubTimestamp":1730806534,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $14.27M, consensus $14.86M. Beam expects that its cash, cash equivalents and marketable securities as of September 30, 2024, wil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-reports-q3-eps-1-17-consensus-1-13?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-reports-q3-eps-1-17-consensus-1-13?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2481571064","title":"Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2481571064","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481571064?lang=en_us&edition=fundamental","pubTime":"2024-11-05 19:32","pubTimestamp":1730806345,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/11/41740155/beam-therapeutics-ended-third-quarter-2024-with-925-8m-in-cash-cash-equivalents-and-marketable-se","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BEAM"],"gpt_icon":0},{"id":"2481571094","title":"Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2481571094","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481571094?lang=en_us&edition=fundamental","pubTime":"2024-11-05 19:30","pubTimestamp":1730806200,"startTime":"0","endTime":"0","summary":"Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting 35 Patients Enrolled and Eight Pat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2974741/0/en/Beam-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Progress-Across-Priority-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4097","BK4505","SCD","BK4109","BK4535","BK4588","BEAM","LENZ","BK4556","BK4139","PRGS","LU2065732104.USD","ASH","LU2463526074.USD"],"gpt_icon":0},{"id":"2481257189","title":"Camp4 Therapeutics initiated with an Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2481257189","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481257189?lang=en_us&edition=fundamental","pubTime":"2024-11-05 19:21","pubTimestamp":1730805678,"startTime":"0","endTime":"0","summary":"William Blair initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating. Published first on TheFly – the ultimate source for real-t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/camp4-therapeutics-initiated-with-an-outperform-at-william-blair?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/camp4-therapeutics-initiated-with-an-outperform-at-william-blair?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CAMP","LENZ"],"gpt_icon":0},{"id":"2481571332","title":"Camp4 Therapeutics initiated with an Outperform at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2481571332","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481571332?lang=en_us&edition=fundamental","pubTime":"2024-11-05 19:20","pubTimestamp":1730805623,"startTime":"0","endTime":"0","summary":"Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead prog...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/camp4-therapeutics-initiated-with-an-outperform-at-leerink?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/camp4-therapeutics-initiated-with-an-outperform-at-leerink?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","CAMP"],"gpt_icon":0},{"id":"2481575945","title":"Qyuns Therapeutics' Plaque Psoriasis Drug Gets Registration Certificate from Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2481575945","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481575945?lang=en_us&edition=fundamental","pubTime":"2024-11-05 18:48","pubTimestamp":1730803681,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  affiliate Hangzhou Zhongmei Huadong Pharmaceutical has received a drug registration certificate for the ustekinumab injection approved by China's National Medical Products Administration, a Tuesday bourse filing said.The drug has been approved for the treatment of moderate-to-severe plaque psoriasis in adults.The ustekinumab injection was initially developed independently by Qyuns Therapeutics. The company later reached a collaboration agreement with Hangzhou Zhongmei Huadong Pharmaceutical to jointly advance its phase III clinical trial related to the drug.Shares of the biotechnology company closed nearly 2% higher on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02509","BK4139","LENZ","BK1161"],"gpt_icon":0},{"id":"2481520577","title":"Camp4 Therapeutics initiated with an Overweight at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2481520577","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481520577?lang=en_us&edition=fundamental","pubTime":"2024-11-05 17:55","pubTimestamp":1730800514,"startTime":"0","endTime":"0","summary":"JPMorgan initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $23 price target The firm says its bullish thesis is based o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/camp4-therapeutics-initiated-with-an-overweight-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/camp4-therapeutics-initiated-with-an-overweight-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","CAMP"],"gpt_icon":0},{"id":"2481520578","title":"Neumora Therapeutics downgraded to Neutral from Overweight at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2481520578","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481520578?lang=en_us&edition=fundamental","pubTime":"2024-11-05 17:55","pubTimestamp":1730800507,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Tessa Romero downgraded Neumora Therapeutics (NMRA) to Neutral from Overweight with a price target of $15, down from $18. Results ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-downgraded-to-neutral-from-overweight-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-downgraded-to-neutral-from-overweight-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","LENZ"],"gpt_icon":0},{"id":"2481152068","title":"Camp4 Therapeutics initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2481152068","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481152068?lang=en_us&edition=fundamental","pubTime":"2024-11-05 17:50","pubTimestamp":1730800209,"startTime":"0","endTime":"0","summary":"Piper Sandler initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $18 price target The company is is pioneering developme...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/camp4-therapeutics-initiated-with-an-overweight-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/camp4-therapeutics-initiated-with-an-overweight-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CAMP","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0025},{"period":"1month","weight":0.1028},{"period":"3month","weight":0.2072},{"period":"6month","weight":0.7571},{"period":"1year","weight":0.7658},{"period":"ytd","weight":0.5502}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license  agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.187611},{"month":2,"riseRate":0.666667,"avgChangeRate":0.15153},{"month":3,"riseRate":0,"avgChangeRate":-0.19103},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.06634},{"month":5,"riseRate":0,"avgChangeRate":-0.187229},{"month":6,"riseRate":0.666667,"avgChangeRate":0.07217},{"month":7,"riseRate":0.5,"avgChangeRate":0.062427},{"month":8,"riseRate":0.25,"avgChangeRate":-0.053734},{"month":9,"riseRate":0.5,"avgChangeRate":-0.017856},{"month":10,"riseRate":0.75,"avgChangeRate":0.006056},{"month":11,"riseRate":0.5,"avgChangeRate":-0.080031},{"month":12,"riseRate":0.666667,"avgChangeRate":0.157581}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}